Sanofi acquires Cambridge mRNA startup for $470M
Sanofi is looking to get into the mRNA game.
The French pharmaceutical giant, the parent of Cambridge-based Sanofi Genzyme, has acquired Tidal Therapeutics, a startup developing nanoparticles that deliver genetic instructions to reprogram immune cells with messenger RNA, or mRNA. Even though Tidal is still in the preclinical stage and does n ot yet have a website, Sanofi paid $160 million up front for the startup, with up to $310 million more in milestone payments.
Founded in 2019, Tidal is a resident…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Rowan Walrath Source Type: news
More News: American Health | France Health | Genetics | Health Management | Nanotechnology | Websites